Group 1 - The core viewpoint of the news highlights the recent stock performance of CloudTop New Horizon (01952.HK), which closed at HKD 67.000, a slight decrease of 0.15% from the previous trading day, with an intraday high of HKD 69.800, marking a new high in nearly a year [1] - The company experienced a net outflow of HKD 37.6499 million in capital on the day, with unspecified amounts flowing in and out [1] Group 2 - CloudTop New Horizon Limited is a Hong Kong-listed biopharmaceutical company focused on the research, clinical development, manufacturing, and commercialization of innovative drugs and vaccines, aiming to meet unmet medical needs in Greater China and other Asian markets [2] - The management team possesses extensive expertise and experience in high-quality research and development, clinical development, regulatory affairs, chemical manufacturing and control (CMC), business development, operations, and commercialization within the pharmaceutical industry [2] - The company has established a portfolio of globally first-in-class or best-in-class drugs and vaccines in areas such as nephrology, mRNA platforms, infectious and communicable diseases, and autoimmune diseases [2] - CloudTop New Horizon initiated commercial listing in 2021 and is building a professional and efficient commercialization team to accelerate product commercialization in Greater China and other Asia-Pacific markets [2] - The company is committed to becoming a leading biopharmaceutical company in Asia, focusing on the development and commercialization of innovative drugs and vaccines to meet the growing medical needs in China and globally, with a mission to enhance human health and well-being [2]
云顶新耀盘中最高价触及69.800港元，创近一年新高